PURPOSE: The Italian National Centre for Oncological Hadrontherapy (Centro Nazionale di Adroterapia Oncologica, CNAO), equipped with a proton and ion synchrotron, started clinical activity in September 2011. The clinical and technical characteristics of the first ten proton beam radiotherapy treatments are reported. MATERIALS AND METHODS: Ten patients, six males and four females (age range 27-73 years, median 55.5), were treated with proton beam radiotherapy. After one to two surgical procedures, seven patients received a histological diagnosis of chordoma (of the skull base in three cases, the cervical spine in one case and the sacrum in three cases) and three of low-grade chondrosarcoma (skull base). Prescribed doses were 74 GyE for chordoma and 70 GyE for chondrosarcoma at 2 GyE/fraction delivered 5 days per week. RESULTS: Treatment was well tolerated without toxicity-related interruptions. The maximal acute toxicity was grade 2, with oropharyngeal mucositis, nausea and vomiting for the skull base tumours, and grade 2 dermatitis for the sacral tumours. After 6-12 months of follow-up, no patient developed tumour progression. CONCLUSIONS: The analysis of the first ten patients treated with proton therapy at CNAO showed that this treatment was feasible and safe. Currently, patient accrual into these as well as other approved protocols is continuing, and a longer follow-up period is needed to assess tumour control and late toxicity.
PURPOSE: The Italian National Centre for Oncological Hadrontherapy (Centro Nazionale di Adroterapia Oncologica, CNAO), equipped with a proton and ion synchrotron, started clinical activity in September 2011. The clinical and technical characteristics of the first ten proton beam radiotherapy treatments are reported. MATERIALS AND METHODS: Ten patients, six males and four females (age range 27-73 years, median 55.5), were treated with proton beam radiotherapy. After one to two surgical procedures, seven patients received a histological diagnosis of chordoma (of the skull base in three cases, the cervical spine in one case and the sacrum in three cases) and three of low-grade chondrosarcoma (skull base). Prescribed doses were 74 GyE for chordoma and 70 GyE for chondrosarcoma at 2 GyE/fraction delivered 5 days per week. RESULTS: Treatment was well tolerated without toxicity-related interruptions. The maximal acute toxicity was grade 2, with oropharyngeal mucositis, nausea and vomiting for the skull base tumours, and grade 2 dermatitis for the sacral tumours. After 6-12 months of follow-up, no patient developed tumour progression. CONCLUSIONS: The analysis of the first ten patients treated with proton therapy at CNAO showed that this treatment was feasible and safe. Currently, patient accrual into these as well as other approved protocols is continuing, and a longer follow-up period is needed to assess tumour control and late toxicity.
Authors: A J Lomax; T Bortfeld; G Goitein; J Debus; C Dykstra; P A Tercier; P A Coucke; R O Mirimanoff Journal: Radiother Oncol Date: 1999-06 Impact factor: 6.280
Authors: Lily Park; Thomas F Delaney; Norbert J Liebsch; Francis J Hornicek; Saveli Goldberg; Henry Mankin; Andrew E Rosenberg; Daniel I Rosenthal; Herman D Suit Journal: Int J Radiat Oncol Biol Phys Date: 2006-06-06 Impact factor: 7.038
Authors: E B Hug; L N Loredo; J D Slater; A DeVries; R I Grove; R A Schaefer; A E Rosenberg; J M Slater Journal: J Neurosurg Date: 1999-09 Impact factor: 5.115
Authors: A Terahara; A Niemierko; M Goitein; D Finkelstein; E Hug; N Liebsch; D O'Farrell; S Lyons; J Munzenrider Journal: Int J Radiat Oncol Biol Phys Date: 1999-09-01 Impact factor: 7.038
Authors: Daniela Schulz-Ertner; Anna Nikoghosyan; Christoph Thilmann; Thomas Haberer; Oliver Jäkel; Christian Karger; Gerhard Kraft; Michael Wannenmacher; Jürgen Debus Journal: Int J Radiat Oncol Biol Phys Date: 2004-02-01 Impact factor: 7.038
Authors: G Fattori; M Riboldi; M Desplanques; B Tagaste; A Pella; R Orecchia; G Baroni Journal: IEEE Trans Biomed Eng Date: 2012-05-11 Impact factor: 4.538
Authors: Arjun Sahgal; Michael W Chan; Eshetu G Atenafu; Laurence Masson-Cote; Gaurav Bahl; Eugene Yu; Barbara-Ann Millar; Caroline Chung; Charles Catton; Brian O'Sullivan; Jonathan C Irish; Ralph Gilbert; Gelareh Zadeh; Michael Cusimano; Fred Gentili; Normand J Laperriere Journal: Neuro Oncol Date: 2014-12-27 Impact factor: 12.300